<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03004625</url>
  </required_header>
  <id_info>
    <org_study_id>AI444-406</org_study_id>
    <nct_id>NCT03004625</nct_id>
  </id_info>
  <brief_title>Daclatasvir, Asunaprevir Plus Ribavirin for HCV Genotype 1b Without NS5A RAV</brief_title>
  <official_title>Treatment Efficacy and Safety of 12 Weeks of Daclatasvir, Asunaprevir Plus Ribavirin for HCV Genotype 1b Without Baseline NS5A Resistance-associated Variants (DARING)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kaohsiung Medical University Chung-Ho Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chang Gung Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Taipei Veterans General Hospital, Taiwan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>China Medical University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cheng-Kung University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Kaohsiung Medical University Chung-Ho Memorial Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A single-arm, multi-center study of HCV-1b patients without baseline non-structure protein
      (NS5A) resistance-associated variants. Daclatasvir (60mg/day) and asunaprevir (100 mg twice
      daily) plus weight-based ribavirin (1000-1200 mg/d) for 12 weeks will be prescribed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Twenty-four weeks of Daclatasvir plus Asunaprevir provided a high treatment efficacy in
      hepatitis C virus genotype 1b (HCV-1b) patients. Patients with non-structural protein 5A
      (NS5A) resistance associated variants (RAVs) would have an inferior response. The
      investigators anticipate that12 weeks of daclatasvir and asunaprevir plus ribavirin is highly
      effective for HCV Genotype 1b patients without baseline NS5A RAVs.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the treatment efficacy (SVR12) of 12 weeks of daclatasvir and asunaprevir plus ribavirin for HCV-1b patients without baseline RAVs</measure>
    <time_frame>6 months (including 3 months of treatment and 3 months of post-treatment follow-up peroid</time_frame>
    <description>SVR12 is defined as undetectable HCV RNA 12 weeks throughout 12 weeks of post-treatment follow-up peroid</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the number of participants with treatment-related adverse events of 12 weeks of daclatasvir and asunaprevir plus ribavirin for HCV-1b patients without baseline RAVs.</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Study Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HCV-1b patients without baseline NS5A resistance-associated variants receiving Daclatasvir (60mg/day) and asunaprevir (100 mg twice daily) plus weight-based ribavirin (1000-1200 mg/d) for 12 weeks. (daclatasvir, asunaprevir plus ribavirin)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>daclatasvir</intervention_name>
    <description>to evaluate the treatment efficacy and safety of the drug in HCV patients</description>
    <arm_group_label>Study Arm</arm_group_label>
    <other_name>Daklinza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>asunaprevir</intervention_name>
    <description>to evaluate the treatment efficacy and safety of the drug in HCV patients</description>
    <arm_group_label>Study Arm</arm_group_label>
    <other_name>Sunvepra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>to evaluate the treatment efficacy and safety of the drug in HCV patients</description>
    <arm_group_label>Study Arm</arm_group_label>
    <other_name>Robatrol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Treatment naïve, interferon-experienced, interferon-intolerant or
             interferon-ineligible, HCV genotype 1b patients with compensated liver disease.

          2. Patients with compensated liver cirrhosis will be capped at 40%.

             Cirrhosis is defined as any one of the following:

               -  Liver biopsy showing cirrhosis

               -  Fibroscan indicative of cirrhosis as evidenced by a result &gt; 12.5 kilopascal

             Absence of cirrhosis is defined as any one of the following:

               -  Liver biopsy within 2 years of Screening showing absence of cirrhosis

               -  Fibroscan within 6 months of Baseline with a result of ≤ 12.5 kilopascal

          3. History of chronic HCV infection &gt; 6 months

          4. Aged at least 20 years

          5. HCV RNA of 10,000 IU/mL or greater

          6. Negative serum or urine pregnancy test result (sensitivity of 25 international units
             or better) for women with childbearing potential within the 24-hour period before the
             first dose of study drugs

          7. Female patients with childbearing potential must agree to use two reliable forms of
             effective non-hormonal contraception (i.e., condoms, cervical barriers, intrauterine
             device, spermicides, or sponge), at least 1 of which must be a physical barrier
             method, during treatment and for at least 6 months following the last dose of
             ribavirin.

          8. A hormonal contraception (in lieu of non-hormonal) plus a physical barrier method can
             be used after end of treatment. All men with female partners of childbearing potential
             must use two reliable forms of effective contraception (combined) during treatment and
             for 6 months following the last dose of ribavirin

          9. Ability to participate and willingness to give written informed consent and to comply
             with the study restrictions.

        Exclusion Criteria:

          1. The existence of baseline NS5A RAV &quot;Lycine 31 (L31F/I/M)&quot; or &quot;Tyrosine93 (Y93H)&quot;, by
             using direct-sequencing with RAV of &gt; 20%.

          2. Hepatitis B virus or HIV co-infection.

          3. Patients with experience of ascites, oesophageal varices, or other evidence of hepatic
             decompensation, and/or hepatocellular carcinoma.

          4. History of organ transplantation, except cornea transplantation.

          5. Hemoglobin concentration &lt; 12 g/dl for male, 11 g/dl for female

          6. Platelet count &lt; 50,000/mm3

          7. Prior direct antiviral agents (DAAs) experienced.

          8. History of active malignancy within the last 5 years, with the exception of localized
             or in situ carcinoma (e.g., basal or squamous cell carcinoma of the skin)

          9. History of severe cardiac disease (e.g., New York Heart Association Functional Class
             III or IV, myocardial infarction within 6 months, ventricular tachyarrhythmia's
             requiring ongoing treatment, unstable angina or other unstable, uncontrolled or
             significant cardiovascular disease within 6 months).

         10. Poorly controlled diabetes (Hemoglobin A1c value ≥ 8.5%) and endocrine condition.

         11. Total bilirubin &gt;2 mg/dL, unless subject has a documented history of Gilbert's
             disease.

         12. Creatinine Clearance (CrCl) &lt;30 mL/min (as estimated by Cockcroft and Gault)

         13. Pregnant or lactating women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ming-Lung Yu, MD., PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kaohsiung Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ming-Lung Yu, MD., PhD.</last_name>
    <phone>88673121101</phone>
    <phone_ext>7475</phone_ext>
    <email>fish6069@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kaohsiung Medical Universsity</name>
      <address>
        <city>Kaohsiung</city>
        <zip>807</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ming-Lung Yu, MD., PhD.</last_name>
      <phone>88673121101</phone>
      <phone_ext>7475</phone_ext>
      <email>fish6069@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Chung-Feng Huang, MD., PhD.</last_name>
      <phone>88673121101</phone>
      <phone_ext>7475</phone_ext>
      <email>fengcheerup@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 21, 2016</study_first_submitted>
  <study_first_submitted_qc>December 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 29, 2016</study_first_posted>
  <last_update_submitted>February 28, 2017</last_update_submitted>
  <last_update_submitted_qc>February 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

